Article
Hematology
Karthik Nath, Jasme Lee, Theresa A. Elko, Lauren Levy, Elaina Preston, Sean M. Devlin, Doris M. Ponce, Richard J. Lin, Brian C. Shaffer, Christina Cho, Ioannis Politikos, Ann A. Jakubowski, Jae H. Park, Raajit Rampal, Miguel-Angel Perales, Martin S. Tallman, Juliet N. Barker, Ellin Berman, Roni Tamari, Eytan Stein, Sergio A. Giralt, Boglarka Gyurkocza
Summary: This study aimed to determine the rate of allo-HCT and the reasons for not undergoing transplant in patients deemed eligible. It was found that although allo-HCT is a potential curative treatment for acute leukemia, only a minority of patients proceeded to transplant. The main barriers to transplant were disease control and early patient death. Further improvements in transplant strategies and induction regimens may increase allo-HCT utilization.
AMERICAN JOURNAL OF HEMATOLOGY
(2023)
Article
Biophysics
Patrick J. Hayden, Dirk-Jan Eikema, Liesbeth C. de Wreede, Linda Koster, Nicolaus Kroger, Hermann Einsele, Monique Minnema, Alida Dominietto, Michael Potter, Jacob Passweg, Arancha Bermudez, Stephanie Nguyen-quoc, Uwe Platzbecker, Johanna Tischer, Fabio Ciceri, Joan Hendrik Veelken, Per Ljungman, Nicolaas Schaap, Edouard Forcade, Angelo Michele Carella, Virginie Gandemer, William Arcese, Adrian Bloor, Attilio Olivieri, Laure Vincent, Meral Beksac, Stefan Schonland, Ibrahim Yakoub-Agha
Summary: For patients with relapsed multiple myeloma, receiving a second allo-HCT from a HLA-identical sibling donor for both transplants is associated with higher overall survival rates. Additionally, an interval of more than 2 years between transplants is associated with superior 5-year survival rates.
BONE MARROW TRANSPLANTATION
(2021)
Article
Biophysics
Ryszard Swoboda, Myriam Labopin, Sebastian Giebel, Thomas Schroeder, Nicolaus Kroeger, Mutlu Arat, Bipin Savani, Alexandros Spyridonidis, Rose-Marie Hamladji, Victoria Potter, Ana Berceanu, Ibrahim Yakoub-Agha, Alessandro Rambaldi, Hakan Ozdogu, Jaime Sanz, Arnon Nagler, Mohamad Mohty
Summary: This study compared two different myeloablative conditioning regimens, FluTBI12 and FB4, before allo-HCT in AML patients. The results showed no significant differences in leukemia-free survival, overall survival, relapse incidence, and non-relapse mortality between the two groups. The incidence of acute and chronic GVHD also showed no statistical differences. In conclusion, FluTBI12 and FB4 are comparable myeloablative regimens for AML patients transplanted in CR1 and CR2.
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Rama Al Hamed, Maud Ngoya, Jacques-Emmanuel Galimard, Henrik Sengeloev, Tobias Gedde-Dahl, Aleksandr Kulagin, Uwe Platzbecker, Ibrahim Yakoub-Agha, Jenny L. Byrne, Thomas Valerius, Gerard Socie, Nicolaus Kroeger, Didier Blaise, Ali Bazarbachi, Jaime Sanz, Fabio Ciceri, Arnon Nagler, Mohamad Mohty
Summary: This retrospective study investigates the impact of time on allogeneic hematopoietic cell transplantation (allo-HCT) outcomes for patients with acute myeloid leukemia (AML) in second complete remission (CR2). The results show that outcomes of allo-HCT in CR2 have significantly improved over time, with the most favorable outcomes achieved with a matched sibling donor (MSD).
Article
Hematology
Masatomo Kuno, Satoshi Yamasaki, Nobuharu Fujii, Yasushi Ishida, Takahiro Fukuda, Keisuke Kataoka, Naoyuki Uchida, Yuta Katayama, Maho Sato, Daishi Onai, Toshihiro Miyamoto, Shuichi Ota, Satoshi Yoshioka, Takahide Ara, Akira Hangaishi, Yoshiko Hashii, Makoto Onizuka, Tatsuo Ichinohe, Yoshiko Atsuta, Yoshihiro Inamoto
Summary: The study compared myeloid neoplasms (MNs) following allogeneic hematopoietic cell transplantation (HCT) versus autologous HCT using a Japanese HCT registry database. The cumulative incidence of MNs was lower after allogeneic HCT than after autologous HCT, and those following allogeneic HCT developed in younger patients and sooner after HCT. Further research is needed to understand the mechanisms of MN development following allogeneic HCT.
AMERICAN JOURNAL OF HEMATOLOGY
(2022)
Article
Hematology
Feiyan Mo, Norihiro Watanabe, Kayleigh I. Omdahl, Phillip M. Burkhardt, Xiaoyun Ding, Eiko Hayase, Angela Panoskaltsis-Mortari, Robert R. Jenq, Helen E. Heslop, Leslie S. Kean, Malcolm K. Brenner, Victor Tkachev, Maksim Mamonkin
Summary: OX40 plays a central role in aGVHD by regulating activation and expansion of T cells. Researchers have developed a specific OX40 cytotoxic receptor that selectively eliminates OX40-positive T cells, reducing the occurrence of aGVHD. Furthermore, combining OX40 targeting with leukemia-specific chimeric antigen receptor provides simultaneous protection against leukemia and aGVHD in post-transplant residual disease.
Article
Microbiology
Shiela McCollam, James S. Lewis, Joseph Bubalo, Amber Diaz
Summary: This study aimed to evaluate the efficacy and safety of 300-mg once-monthly intravenous (IV) pentamidine prophylaxis in 702 adult allogeneic hematopoietic stem cell transplant (HSCT) patients. The results showed that IV pentamidine administration effectively prevented Pneumocystis jirovecii pneumonia (PJP), but breakthrough Nocardia and Toxoplasma infections were observed in a certain percentage of patients.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Review
Cell Biology
Julia Froebel, Theresa Landspersky, Guelce Percin, Christina Schreck, Susann Rahmig, Alessandro Ori, Daniel Nowak, Marieke Essers, Claudia Waskow, Robert A. J. Oostendorp
Summary: The bone marrow environment, known as the niche, plays a vital role in maintaining blood cell formation throughout life. Different types of stress can disrupt the niche, leading to deregulation of hematopoietic stem cells and their function. Both acute and chronic insults can alter the cellular composition and structure of the niche, ultimately affecting hematopoiesis and increasing susceptibility to diseases.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Hematology
Sami B. Kanaan, Francesca Urselli, Jerald P. Radich, J. Lee Nelson
Summary: By using a highly sensitive chimerism assay, this study demonstrates the ability to predict the risk of relapse in leukemia patients after allogeneic hematopoietic cell transplant. Compared to traditional measurement methods, this assay provides more accurate detection of recipient cells and, when combined with flow cytometry, improves the prediction of relapse risk. This technology is important for early intervention.
Article
Biophysics
Shinsuke Takagi, Sho Ogura, Hideki Araoka, Naoyuki Uchida, Takashi Mitsuki, Mitsuhiro Yuasa, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Muneyoshi Kimura, Kazuya Ishiwata, Hisashi Yamamoto, Go Yamamoto, Yuki Asano-Mori, Yukako Koike, Koji Izutsu, Atsushi Wake, Shigeyoshi Makino, Akiko Yoneyama, Shuichi Taniguchi
Summary: The study found that the incidence of BSI after allogeneic HCT is significantly impacted by the source of graft cells, with U-CB transplantation posing the highest risk. Among U-CB recipients, those not in remission at the time of transplantation face the greatest risk of BSI.
BONE MARROW TRANSPLANTATION
(2021)
Article
Immunology
Hanne Beeckmans, Gene P. L. Ambrocio, Saskia Bos, Astrid Vermaut, Vincent Geudens, Arno Vanstapel, Bart M. Vanaudenaerde, Frans De Baets, Thomas L. A. Malfait, Marie-Paule Emonds, Dirk E. Van Raemdonck, Helene M. Schoemans, Robin Vos, Leuven Lung Transplant Grp
Summary: Pulmonary alveolar proteinosis (PAP) is a rare lung disorder characterized by surfactant accumulation, and lung transplantation followed by hematopoietic stem cell transplantation may be an effective treatment for end-stage hereditary PAP-induced pulmonary fibrosis.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Elena Kum, Gabriele Jagelaviciute, Edward Li, Kenneth Williams, Santhosh Thyagu, Warren Fingrut
Summary: The article tells the story of a Canadian stem cell recipient who underwent transplantation from a matched unrelated donor for refractory chronic myelogenous leukemia, showcasing different perspectives and encouraging people to become donors.
Article
Biophysics
Zixuan Zhang, Yuta Hasegawa, Daigo Hashimoto, Hajime Senjo, Ryo Kikuchi, Xuanzhong Chen, Kazuki Yoneda, Tomoko Sekiguchi, Tatsuya Kawase, Hirofumi Tsuzuki, Takashi Ishio, Takahide Ara, Hiroyuki Ohigashi, Masao Nakagawa, Takanori Teshima
Summary: This study found that short-term administration of the selective FLT3 inhibitor, gilteritinib, after allo-SCT can enhance the immune response against FLT3-ITD+ leukemia and significantly improve survival rate.
BONE MARROW TRANSPLANTATION
(2022)
Article
Nutrition & Dietetics
Mei Yan, Jian Pan, Jie Huang, Changwei Liu, Xiaona Xia, Ting Zhu, Yuanyuan Wan, Yongjun Fang, Weibing Tang
Summary: This study evaluated the nutritional status of children who underwent allogeneic hematopoietic stem cell transplantation (alloHSCT) in the first 100 days. The study aimed to clarify the effect of weight loss on clinical outcomes and to analyze factors influencing weight loss. Data from 80 pediatric patients were collected and analyzed to investigate the factors affecting weight loss and the impact of weight loss on clinical outcomes.
FRONTIERS IN NUTRITION
(2023)
Article
Oncology
Sebastian Giebel, Myriam Labopin, Urpu Salmenniemi, Gerard Socie, Sergey Bondarenko, Didier Blaise, Nicolaus Kroeger, Jan Vydra, Anna Grassi, Francesca Bonifazi, Tomasz Czerw, Achilles Anagnostopoulos, Bruno Lioure, Annalisa Ruggeri, Bipin Savani, Alexandros Spyridonidis, Jaime Sanz, Zinaida Peric, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
Summary: This study compared the efficacy of using rabbit antithymocyte globulin (ATG) and posttransplant cyclophosphamide (PTCY) as immunosuppressive strategies for prophylaxis of graft-versus-host disease (GVHD) in acute lymphoblastic leukemia (ALL) patients. The study found that while the PTCY group had a reduced risk of chronic GVHD, it also had inferior leukemia-free survival compared to the ATG group.
Letter
Hematology
Annalisa Ruggeri, Liesbeth C. de Wreede, Carlheinz R. Muller, Pietro Crivello, Edouard F. Bonneville, Effie W. Petersdorf, Gerard Socie, Valerie Dubois, Riitta Niittyvuopio, Juha Perasaari, Ibrahim Yakoub-Agha, Jan J. Cornelissen, Lotte Wieten, Tobias Gedde-Dahl, Edouard Forcade, Charles R. Crawley, Steven G. E. Marsh, Virginie Gandemer, Eleni Tholouli, Claude-Eric Bulabois, Anne Huynh, Goda Choi, Eric Deconinck, Maija Itala-Remes, Stig Lenhoff, Mats Bengtsson, Jan-Erik Johansson, Gwendolyn van Gorkom, Jorinde D. Hoogenboom, Luca Vago, Vanderson Rocha, Chiara Bonini, Christian Chabannon, Katharina Fleischhauer
Article
Oncology
Victoria Stavrou, Livingstone Fultang, Sarah Booth, Daniele De Simone, Arekdiusz Bartnik, Ugo Scarpa, Luciana Gneo, Silvia Panetti, Sandeep Potluri, Meaad Almowaled, Jonathan Barlow, Andris Jankevics, Gavin Lloyd, Andrew Southam, David A. Priestman, Paul Cheng, Warwick Dunn, Frances Platt, Hitoshi Endou, Charles Craddock, Karen Keeshan, Francis Mussai, Carmela De Santo
Summary: Acute myeloid leukaemia (AML) creates an immunosuppressive environment through induced arginine depletion. Serum amyloid A (SAA) in AML upregulates ARG2 expression, promotes cell viability, and activates iNKT cells, resulting in AML cell death. Therefore, stimulating iNKT cell activity has potential as an immunotherapy for AML.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Hematology
Elise Sourdeau, Ludovic Suner, Mara Memoli, Alexis Genthon, Frederic Feger, Lou Soret, Nassera Abermil, Laurence Heuberger, Chrystele Bilhou-Nabera, Helene Guermouche, Fabrizia Favale, Simona Lapusan, Michael Chaquin, Claire Hirschauer, Mohamad Mohty, Ollivier Legrand, Francois Delhommeau, Pierre Hirsch
Summary: Chemotherapy resistance is the main cause of treatment failure in acute myeloid leukemia (AML) and is related to ATP-binding cassette transporter activity. This study investigates the relationships between ABC activity, immunophenotypic, cytogenetic, molecular, and targeted next-generation sequencing features in AML patients. High ABC activity is associated with certain characteristics (less proliferating disease, immature immunophenotype, gene mutations defining secondary-type AML), while low ABC activity is associated with different characteristics (more mature myeloid differentiation, monocytic commitment, certain gene mutations defining de novo-type AML). ABC activity can be used to predict AML ontogeny and may be an independent factor for event-free survival when considered with full molecular data.
Article
Oncology
Arnon Nagler, Jacques-Emmanuel Galimard, Myriam Labopin, Didier Blaise, William Arcese, Silvia Maria Trisolini, Depei Wu, Arnaud Pigneux, Gwendolyn Van Gorkom, Marie-Therese Rubio, Tobias Gedde-Dahl, Anne Huynh, Francesco Lanza, Norbert-Claude Gorin, Mohamad Mohty
Summary: AML patients who required two chemotherapy courses to achieve complete remission had inferior leukemia free survival and overall survival rates, as well as higher relapse incidence. Allogeneic transplantation may be a better option for these patients to improve outcomes.
Editorial Material
Hematology
Jean-Luc Harousseau, Mohamad Mohty
Article
Hematology
Anais Schavgoulidze, Alexis Talbot, Aurore Perrot, Titouan Cazaubiel, Xavier Leleu, Salomon Manier, Laure Buisson, Sabrina Maheo, Laura Do Souto Ferreira, Luka Pavageau, Cyrille Hulin, Jean-Pierre Marolleau, Laurent Voillat, Karim Belhadj, Marion Divoux, Borhane Slama, Sabine Brechignac, Margaret Macro, Anne-Marie Stoppa, Laurence Sanhes, Frederique Orsini-Piocelle, Jean Fontan, Marie-Lorraine Chretien, Helene Demarquette, Mohamad Mohty, Herve Avet-Loiseau, Jill Corre
Summary: Our study aimed to confirm the adverse effect of 1p32 deletion in patients with newly diagnosed multiple myeloma (NDMM). We found that patients with del(1p32) had significantly inferior overall survival and progression-free survival compared to those without del(1p32). Biallelic del(1p32) conferred a dramatically poorer prognosis than monoallelic del(1p32).
Article
Biophysics
Mohamad Mohty, Didier Blaise, Regis Peffault de Latour, Myriam Labopin, Jean Henri Bourhis, Benedicte Bruno, Patrice Ceballos, Marie Detrait, Virginie Gandemer, Anne Huynh, Faezeh Izadifar-Legrand, Charlotte Jubert, Helene Labussiere-Wallet, Delphine Lebon, Sebastien Maury, Catherine Paillard, Cecile Pochon, Cecile Renard, Fanny Rialland, Pascale Schneider, Anne Sirvent, Kobby Asubonteng, Gwennaelle Guindeuil, Ibrahim Yakoub-Agha, Jean-Hugues Dalle
Summary: This study evaluated the effectiveness and safety of defibrotide in patients undergoing haematopoietic cell transplantation (HCT). The results showed that defibrotide had a good effect in treating severe/very severe VOD/SOS, with high survival and complete response rates.
BONE MARROW TRANSPLANTATION
(2023)
Article
Biophysics
Ryszard Swoboda, Myriam Labopin, Sebastian Giebel, Thomas Schroeder, Nicolaus Kroeger, Mutlu Arat, Bipin Savani, Alexandros Spyridonidis, Rose-Marie Hamladji, Victoria Potter, Ana Berceanu, Ibrahim Yakoub-Agha, Alessandro Rambaldi, Hakan Ozdogu, Jaime Sanz, Arnon Nagler, Mohamad Mohty
Summary: This study compared two different myeloablative conditioning regimens, FluTBI12 and FB4, before allo-HCT in AML patients. The results showed no significant differences in leukemia-free survival, overall survival, relapse incidence, and non-relapse mortality between the two groups. The incidence of acute and chronic GVHD also showed no statistical differences. In conclusion, FluTBI12 and FB4 are comparable myeloablative regimens for AML patients transplanted in CR1 and CR2.
BONE MARROW TRANSPLANTATION
(2023)
Article
Biophysics
Klaus Hirschbuehl, Myriam Labopin, Emmanuelle Polge, Didier Blaise, Jean Henri Bourhis, Gerard Socie, Edouard Forcade, Ibrahim Yakoub-Agha, Helene Labussiere-Wallet, Wolfgang Bethge, Patrice Chevallier, Sarah Bonnet, Matthias Stelljes, Alexandros Spyridonidis, Zinaida Peric, Eolia Brissot, Bipin Savani, Sebastian Giebel, Christoph Schmid, Fabio Ciceri, Arnon Nagler, Mohamad Mohty
Summary: Allogeneic hematopoietic cell transplantation is a curative treatment for high-risk acute lymphoblastic leukemia, and conditioning regimens based on 12 Gray total body irradiation are the standard for patients under 45 years old. However, elderly patients often receive intermediate intensity conditioning to reduce toxicity. A retrospective study compared the outcomes of different conditioning regimens in ALL patients over 45 years old.
BONE MARROW TRANSPLANTATION
(2023)
Article
Biophysics
Iman Abou Dalle, Myriam Labopin, Nicolaus Kroeger, Thomas Schroeder, Juergen Finke, Matthias Stelljes, Andreas Neubauer, Didier Blaise, Ibrahim Yakoub-Agha, Urpu Salmenniemi, Edouard Forcade, Maija Itala-Remes, Peter Dreger, Gesine Bug, Jakob Passweg, Michael Heuser, Goda Choi, Eolia Brissot, Sebastian Giebel, Arnon Nagler, Fabio Ciceri, Ali Bazarbachi, Mohamad Mohty
Summary: Pre-transplant detectable measurable residual disease (MRD) is still associated with high risk of relapse and poor outcomes in acute myeloid leukemia (AML). The impact of disease burden on prediction of relapse and survival in patients receiving allogeneic hematopoietic cell transplantation (allo-HCT) in first remission (CR1) was evaluated. The study found that patients in CR1 and MRD positive at time of transplant could still be salvaged by allo-HCT, with significantly better outcomes than patients transplanted with active disease.
BONE MARROW TRANSPLANTATION
(2023)
Article
Biophysics
Jan Styczynski, Gloria Tridello, Linda Koster, Nina Knelange, Lotus Wendel, Anja van Biezen, Steffie van der Werf, Malgorzata Mikulska, Lidia Gil, Catherine Cordonnier, Per Ljungman, Diana Averbuch, Simone Cesaro, Helen Baldomero, Christian Chabannon, Selim Corbacioglu, Harry Dolstra, Bertram Glass, Raffaella Greco, Nicolaus Kroeger, Regis Peffault de Latour, Mohamad Mohty, Benedicte Neven, Zinaida Peric, John A. Snowden, Anna Sureda, Ibrahim Yakoub-Agha, Rafael de la Camara
Summary: This study analyzed the incidence and specific causes of death in HCT patients, focusing on infectious deaths. The results showed a decrease in mortality from infections in early phases but an increase in mortality from bacterial infections in the late phase.
BONE MARROW TRANSPLANTATION
(2023)
Article
Biophysics
Jean El Cheikh, Ghassan Bidaoui, Ali Atoui, Khodr Terro, Layal Sharrouf, Ammar Zahreddine, Nour Moukalled, Imane Abou Dalle, Ali Bazarbachi, Mohamad Mohty, Remy Dulery
Summary: This study evaluates the outcome of high-risk hematological malignancies patients who received Clo/TBI (4-8 Gy) as a conditioning regimen before allo-SCT. It shows that Clo/TBI is effective in disease control with an acceptable toxicity profile for high-risk patients.
BONE MARROW TRANSPLANTATION
(2023)
Article
Medicine, General & Internal
Florent Malard, Ernst Holler, Brenda M. Sandmaier, He Huang, Mohamad Mohty
Summary: Acute graft-versus-host disease (GVHD) is a common immune complication that can occur after allogeneic haematopoietic cell transplantation (alloHCT). This Primer summarizes the epidemiology, pathophysiology, diagnosis, prevention and treatment of this disorder. The article also reviews future research avenues and the effect this disorder has on patients' quality of life.
NATURE REVIEWS DISEASE PRIMERS
(2023)
Article
Biophysics
Alexandros Spyridonidis, Myriam Labopin, Tobias Gedde-Dahl, Arnold Ganser, Matthias Stelljes, Charles Craddock, Eva Maria Wagner-Drouet, Jurjen Versluis, Thomas Schroeder, Igor Wolfgang Blau, Gerald. G. Wulf, Peter Dreger, Gitte Olesen, Henrik Sengeloev, Nicolaus Kroger, Victoria Potter, Edouard Forcade, Jakob Passweg, Regis Peffault de Latour, Johan Maertens, Keith M. O. Wilson, Jean Henri Bourhis, Juergen Finke, Eolia Brissot, Ali Bazarbachi, Sebastian Giebel, Bipin P. Savani, Arnon Nagler, Fabio Ciceri, Mohamad Mohty
Summary: This study confirms the effectiveness of the recently developed transplant conditioning intensity (TCI) score in predicting mortality and relapse rates in hematopoietic cell transplantation.
BONE MARROW TRANSPLANTATION
(2023)
Article
Medicine, Research & Experimental
Vincent Jachiet, Laure Ricard, Pierre Hirsch, Florent Malard, Laurent Pascal, Odile Beyne-Rauzy, Pierre Peterlin, Alexandre Thibault Jacques Maria, Norbert Vey, Maud D'Aveni, Marie-Pierre Gourin, Sophie Dimicoli-Salazar, Anne Banos, Stefan Wickenhauser, Louis Terriou, Benoit De Renzis, Eric Durot, Shanti Natarajan-Ame, Anne Vekhoff, Laurent Voillat, Sophie Park, Julien Vinit, Celine Dieval, Azeddine Dellal, Vincent Grobost, Lise Willems, Julien Rossignol, Eric Solary, Olivier Kosmider, Nicolas Dulphy, Lin Pierre Zhao, Lionel Ades, Pierre Fenaux, Olivier Fain, Mohamad Mohty, Beatrice Gaugler, Arsene Mekinian
Summary: Background systemic inflammatory and autoimmune diseases (SIADs) occur in a significant proportion of myelodysplastic syndrome (MDS) patients. The recently identified VEXAS syndrome, associated with somatic mutations in UBA1, is characterized by severe inflammatory conditions and hematological abnormalities, including MDS. However, the mechanisms underlying the association between MDS and SIADs are largely unknown. This study aimed to evaluate myeloid immune cell subsets in MDS patients with and without SIAD and compare them to healthy controls.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)